InterCure Ltd. (NASDAQ:INCR - Get Free Report) was the recipient of a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 13,900 shares, a decline of 21.9% from the October 15th total of 17,800 shares. Based on an average daily trading volume, of 28,600 shares, the short-interest ratio is currently 0.5 days. Approximately 0.1% of the company's shares are sold short.
InterCure Stock Performance
Shares of INCR stock traded down $0.07 during mid-day trading on Friday, hitting $1.17. The company's stock had a trading volume of 142,958 shares, compared to its average volume of 54,061. The company's fifty day simple moving average is $1.78 and its 200-day simple moving average is $2.23. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.15 and a current ratio of 1.78. InterCure has a 52 week low of $1.06 and a 52 week high of $3.72.
Institutional Trading of InterCure
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC purchased a new stake in shares of InterCure in the third quarter worth approximately $49,000. Renaissance Technologies LLC boosted its holdings in InterCure by 30.9% during the second quarter. Renaissance Technologies LLC now owns 45,300 shares of the company's stock worth $91,000 after purchasing an additional 10,700 shares during the last quarter. AdvisorShares Investments LLC bought a new position in shares of InterCure during the 2nd quarter worth approximately $218,000. Finally, Tidal Investments LLC bought a new position in shares of InterCure in the first quarter valued at approximately $883,000. 8.34% of the stock is owned by institutional investors.
About InterCure
(
Get Free Report)
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil.
Further Reading
Before you consider InterCure, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InterCure wasn't on the list.
While InterCure currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
